Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC

Annette O. Walter, Robert Tjin Tham Sjin, Henry J. Haringsma, +27

Cancer Discovery

Selective irreversible inhibition of a protease by targeting a noncatalytic cysteine

Margit Hagel, Deqiang Niu, Thia St Martin, +11

Nature Chemical Biology

Selective Irreversible InhibitionBiochemistryProtein FoldingNatural SciencesMedicine +6

Discovery of a Potent and Isoform-Selective Targeted Covalent Inhibitor of the Lipid Kinase PI3Kα

Mariana Nacht, Lixin Qiao, Michael P. Sheets, +12

Journal of Medicinal Chemistry

Drug TargetChemical BiologyCancer BiologyTumor BiologyMolecular Pharmacology +16

<i>In Vitro</i> and <i>In Vivo</i> Characterization of Irreversible Mutant-Selective EGFR Inhibitors That Are Wild-Type Sparing

Robert Tjin Tham Sjin, Kwangho Lee, Annette O. Walter, +21

Molecular Cancer Therapeutics

Drug TargetingNovel TherapyNormal Lung TissueMedicineCancer Growth +12

Protein tyrosine phosphatase PRL-3 in malignant cells and endothelial cells: expression and function

Cécile Rouleau, André Roy, Thia St Martin, +18

Molecular Cancer Therapeutics

Human endothelial precursor cells express tumor endothelial marker 1/endosialin/CD248

Rebecca G. Bagley, Cécile Rouleau, Thia St Martin, +10

Molecular Cancer Therapeutics

Endothelial Cell PathobiologyAngiogenesisEndothelial CellsTumor GrowthImmunology +10

Stem cell-derived clade F AAVs mediate high-efficiency homologous recombination-based genome editing

Laura J. Smith, Jason Wright, Gabriella Clark, +11

Proceedings of the National Academy of Sciences

Superiority of a novel EGFR targeted covalent inhibitor over its reversible counterpart in overcoming drug resistance

Juswinder Singh, Erica N Evans, Margit Hagel, +10

MedChemComm

Drug TargetPharmacotherapyNovel Chemical ScaffoldDrug ResistanceMolecular Pharmacology +16

Tumor endothelial marker 7 (TEM-7): A novel target for antiangiogenic therapy

Rebecca G. Bagley, Cécile Rouleau, William Weber, +9

Microvascular Research

Tumor BiologyAngiogenesisNovel TargetPathologyVascular Biology +8

2.23 Covalent Inhibition of Btk with Clinical Development Compound AVL-292 Disrupts Signaling That Maintains the Microenvironment Necessary for Chronic Lymphocytic Leukemia Growth

Erica N Evans, Sabine Ponader, Russell Karp, +14

Clinical Lymphoma Myeloma & Leukemia

Hematological MalignancyLymphoid NeoplasiaImmunologyCovalent InhibitionMicroenvironment Necessary +4